Disease penetrance of late-onset parkinsonism: A meta-analysis

JAMA Neurology

Volumn 71, Issue 12, 2014, Pages 1535-1539

  Trinh, Joanne ^a   Guella, Ilaria ^a   Farrer, Matthew James ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; DATA BASE; DNAJC13 GENE; EIF4G1 GENE; ETHNIC DIFFERENCE; GENE; GENE DOSAGE; GENE DUPLICATION; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; LRRK2 GENE; MISSENSE MUTATION; ONSET AGE; PARKINSON DISEASE; PENETRANCE; POINT MUTATION; SNCA GENE; VP535 GENE; GENETICS; META ANALYSIS; PARKINSONISM;

AGE OF ONSET; HUMANS; PARKINSONIAN DISORDERS; PENETRANCE;

EID: 84918559074     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1909     Document Type: Article

References (29)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6): 525-535.
2. Pedersen NL, Christensen K, Dahl AK, et al. IGEMS: the consortium on Interplay of Genes and Environment across Multiple Studies. Twin Res Hum Genet. 2013;16(1):481-489.
3. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318.
4. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol. 2013;9(8): 445-454.
5. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006;67(10):1786-1791.
6. Healy DG, Wood NW, Schapira AH. Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol. 2008;8(6):381-385.
7. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354(4):424-425.
8. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol. 2008;7(7):591-594.
9. Trinh J, Amouri R, Duda JE, et al. A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging. 2014;35(5):1125-1131.
10. Deng H, LeW, Davidson AL, XieW, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006;407(2):97-100.
11. Ishihara L, Gibson RA,Warren L, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22(1):55-61.
12. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord. 2006;21(8):1102-1108.
13. Goldwurm S, Tunesi S, Tesei S, et al. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord. 2011;26(11): 2144-2145.
14. Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J AmStat Assoc. 1958;53(282):457-481.
15. Wacholder S, Hartge P, Struewing JP, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol. 1998;148(7):623-630.
16. Reider CR, Halter CA, Castelluccio PF, Oakes D, NicholsWC, Foroud T; Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease. Mov Disord. 2003;18(3):275-279.
17. Ruiz-Martínez J, Gorostidi A, Ibañez B, et al. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov Disord. 2010;25(14):2340-2345.
18. FarrerM, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol. 2004;55(2):174-179.
19. Nishioka K, Ross OA, Ishii K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord. 2009;24(12):1811-1819.
20. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism: dementia. Ann Neurol. 1998;43(6):768-781.
21. Nishioka K, Wider C, Vilariño-Güell C, et al. Association of α-, β-, and ã-synuclein with diffuse Lewy body disease. Arch Neurol. 2010;67(8): 970-975.
22. Golbe LI. α-synuclein and Parkinson's disease. Mov Disord. 1999;14(1):6-9.
23. Obi T, Nishioka K, Ross OA, et al. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology. 2008;70(3):238-241.
24. Mills RD, Mulhern TD, Liu F, Culvenor JG, Cheng HC. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). Hum Mutat. 2014;35(4):395-412.
25. Conway KA, Lee SJ, Rochet JC, et al. Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann N Y Acad Sci. 2000;920:42-45.
26. Wood SJ,Wypych J, Steavenson S, Louis JC, CitronM, Biere AL. α-Synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J Biol Chem. 1999;274(28):19509-19512.
27. Nebel A, Filon D,Weiss DA, et al. High-resolution Y chromosome haplotypes of Israeli and Palestinian Arabs reveal geographic substructure and substantial overlap with haplotypes of Jews. Hum Genet. 2000;107(6): 630-641.
28. Helfer E, Harbour ME, Henriot V, et al. Endosomal recruitment of theWASH complex: active sequences and mutations impairing interaction with the retromer. Biol Cell. 2013;105(5): 191-207.
29. Seaman MN, Gautreau A, Billadeau DD. Retromer-mediated endosomal protein sorting: all WASHed up! Trends Cell Biol. 2013;23(11):522-528.